GENE CELL INC
10QSB, EX-27, 2000-11-22
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: GENE CELL INC, 10QSB, 2000-11-22
Next: FT 416, 24F-2NT, 2000-11-22



<TABLE> <S> <C>

<ARTICLE> 5
<CIK> 0001096637
<NAME> GENE CELL, INC.

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-END>                               SEP-30-2000
<CASH>                                          27,752
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                27,752
<PP&E>                                         263,910
<DEPRECIATION>                                 135,760
<TOTAL-ASSETS>                                 168,750
<CURRENT-LIABILITIES>                          132,732
<BONDS>                                          22632
                                0
                                          0
<COMMON>                                        17,778
<OTHER-SE>                                     (4,413)
<TOTAL-LIABILITY-AND-EQUITY>                   168,750
<SALES>                                              0
<TOTAL-REVENUES>                                 5,471
<CGS>                                                0
<TOTAL-COSTS>                                  566,541
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              11,184
<INCOME-PRETAX>                              (572,254)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          (572,254)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (572,254)
<EPS-BASIC>                                     (0.03)
<EPS-DILUTED>                                   (0.03)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission